Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...
Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...
Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival ...
Abbott has been given U.S. clearance for new updates to its CardioMEMS HF System that allow for patient-facing capabilities ...
A phase 3 lung cancer study of ArriVent BioPharma’s EGFR inhibitor has missed its primary endpoint, sending the biotech’s stock down 57% in early trading.
Forbion has touted its “landmark” 2.3 billion euro ($2.6 billion) fundraise across two funds as a new record for the European ...
Using a short lapidated peptide (SLiP) developed by Mimetic Medicines disrupted a crucial voltage-gated sodium channel ...
Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...
The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease. | The FDA has approved a surgically implanted pulmonary heart valve ...
A more subdued volume of biopharma layoffs continued into the third quarter of 2026, validating predictions that the sector ...
Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...
Genmab has linked an antibody-drug conjugate (ADC) to median progression-free survival (PFS) of 9.5 months, leading TD Cowen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results